Skip to content

NO AXILLARY SURGERY IN EARLY BREAST CANCER (OXIGENATE)

NO AXILLARY SURGERY IN EARLY BREAST CANCER

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07370571
Acronym
OXIGENATE
Enrollment
827
Registered
2026-01-27
Start date
2026-03-01
Completion date
2032-03-30
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

omission SLN, breast cancer

Brief summary

Prospective study will establish a comprehensive international registry specifically for patients who have undergone surgery for primary breast cancer without SLNB. The main objective of this registry is to gather detailed, real-world data on the outcomes of this particular treatment approach, providing insights into the clinical efficacy and quality of life of patients when SLNB is omitted.

Detailed description

All patients with histologically confirmed invasive breast cancer and a negative axillary US who are candidates for omitting SLN biopsy or any axillary surgery will be informed about the possible participation in the study. The inclusion and exclusion criteria are verified by the investigator and written informed consent is obtained from the patient. Surgical treatment, pathological assessment and postoperative locoregional and systemic therapy should be conducted according to institutional and national standards. Since the OXYGENATE study in a non-interventional trial, the study sites do not deviate from their own institutional protocol at any timepoint. The follow up on patient status is conducted yearly during the first 5 years after surgery.

Interventions

PROCEDUREOmission SLN

Omission SLN

Sponsors

Clinica Universidad de Navarra, Universidad de Navarra
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Older than 18 years old cT1-2 cN0 Negative preoperative assessment of the axilla Breast surgery as first treatment No axillary surgery Multifocal/ multicentric breast cancer Candidates to receive breast conserving surgery Written informed consent must be signed and dated by the patient and the investigator prior to inclusion. Patients must be accessible for follow-up.

Exclusion criteria

Synchronous distant metastases Any axillary surgery Neoadjuvant treatment Previous malignancy Bilateral breast cancer Previous primary systemic therapy Pregnancy or breastfeeding Pre-operative diagnosis (cytology or histology) of axillary lymph node metastases Pre-operative radiological evidence of multiple involved or suspicious nodes Patients with psychiatric, addictive, or any disorder, which compromises their ability to give informed consent for participation in this study.

Design outcomes

Primary

MeasureTime frameDescription
Axillary Recurrencefrom enrollement to the end of follow up 5 yearsDetermine the clinical efficacy of omitting a SLN i
3 year axillary recurrence3 yearsIdentify if patients with no axillary surgery had an increased axillary recurrence

Contacts

CONTACTIsabel T Rubio, MD, PhD
irubior@unav.es+34620226830

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026